Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy

BACKGROUND: Immune-mediated myocarditis is an uncommon adverse effect of immune checkpoint inhibition and is associated with a high rate of mortality. METHODS: In this reported case, a 64-year-old woman with right temporo-parietal glioblastoma IDH-WT was treated with nivolumab, temozolomide and radi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tay, Rebecca Y, Blackley, Elizabeth, McLean, Catriona, Moore, Maggie, Bergin, Peter, Gill, Sanjeev, Haydon, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625667/
https://www.ncbi.nlm.nih.gov/pubmed/28797029
http://dx.doi.org/10.1038/bjc.2017.253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625667/
https://www.ncbi.nlm.nih.gov/pubmed/28797029
http://dx.doi.org/10.1038/bjc.2017.253

Ejemplares similares